ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Last trade$1.39
Day change+$0.14 (+11.20%)
Day range$1.25 – $1.42
Volume543,068
Market cap$176M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$175.83M
Price / earnings
—
Price / book
-0.71×
Price / sales
2.07×
EV / sales
1.21×
EV / EBITDA
-1.27×
Profitability
Earnings per share
-$0.58
Return on assets
-31.75%
Return on equity
32.61%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.47×
Current ratio
3.05×
Quick ratio
2.98×
Cash ratio
2.42×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$100.55M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ADCT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$21.72M
$19.25M
$20.85M
$23.06M
$16.43M
$18.84M
$23.03M
$16.91M
Cost of revenue
$1.98M
$2.35M
$3.62M
$1.7M
$1.2M
$836K
$2.06M
$1.37M
Gross profit
$19.74M
$16.9M
$17.24M
$21.36M
$15.23M
$18M
$20.97M
$15.54M
Selling, general and administrative
$19.41M
$22.27M
$22.6M
$21.44M
$19.01M
$18.97M
$20.51M
$20.87M
Research and development
$14.74M
$17.37M
$19.88M
$18.18M
$26.8M
$30.09M
$28.93M
$27.1M
Total operating expenses
$34.09M
$42.31M
$42.48M
$39.28M
$46.19M
$62.15M
$49.44M
$47.98M
Operating income
-$14.35M
-$25.41M
-$25.25M
-$17.92M
-$30.97M
-$44.15M
-$28.46M
-$32.44M
Interest expense
-$13.73M
-$13.51M
-$12.35M
-$13.01M
-$13.39M
-$13M
-$12.23M
-$11.92M
Income before taxes
-$25.3M
-$16.57M
-$32.97M
-$6.81M
-$40.97M
-$55.39M
-$38.44M
-$32.59M
Income taxes
$0
$0
$0
-$404K
$0
$1.25M
$165K
-$321K
Net income
-$25.3M
-$16.57M
-$32.97M
-$6.41M
-$40.97M
-$56.65M
-$38.6M
-$30.73M
Net income attributable to common shareholders
-$25.3M
-$16.57M
-$32.97M
-$6.41M
-$40.97M
-$56.65M
-$38.6M
-$30.73M
EBITDA
-$14.41M
-$22.74M
-$25.25M
-$18.27M
-$30.59M
-$31.06M
-$28.46M
-$32.1M
Basic earnings per share
-$0.16
-$0.11
-$0.21
-$0.04
-$0.30
-$0.50
-$0.36
-$0.29
Diluted earnings per share
-$0.16
-$0.11
-$0.21
-$0.04
-$0.30
-$0.50
-$0.36
-$0.29
Recent news
Company coverage with links to the original publishers.
ADC Therapeutics (ADCT) reported a quarterly loss of $0.16 per share, beating consensus estimates of $0.21 loss, with a 23.81% earnings surprise. Revenue of $21.72 million also exceeded expectations by 5.67%. However, the stock has declined 55.2% year-to-date versus the S&P 500's 7.8% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
BioAge Labs (BIOA) reported a quarterly loss of $0.73 per share, missing consensus estimates by 7.35%, with revenues of $0.3 million falling 66.89% short of expectations. The company's stock has declined 55% year-to-date, and it received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions. The Medical - Biomedical and Genetics industry ranks in the top 45% of sectors.
NeoGenomics reported Q3 2026 earnings of $0.07 per share, beating consensus estimates of $0.06, with revenues of $209.25 million slightly exceeding expectations. The company has outperformed the market by 46.9% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. ADC Therapeutics is expected to report a quarterly loss of $0.21 per share.
Pomerantz LLP is investigating ADC Therapeutics for potential securities fraud following the December 3, 2025 announcement of LOTIS-7 trial data. Despite positive framing, the press release disclosed adverse events in two patients and cytokine release syndrome in 36.7% of patients, triggering a 14.13% stock price decline to $3.95 per share.
Pomerantz LLP announced investigations into potential securities fraud at Graphic Packaging Holding Company, Fermi Inc., and ADC Therapeutics SA. Graphic Packaging specifically lowered its full-year earnings guidance on December 8, 2025, citing production curtailments, resulting in an 8.66% stock price decline to $14.23 per share.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.